Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG
Authors:
- LaMont J. BarlowLBLaMont J. Barlow
- Catherine M. SeagerCSCatherine M. Seager
- Mitchell C. BensonMBMitchell C. Benson
- James M. McKiernanJMJames M. McKiernan
- 1 January 2010
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 28 (1) , 108-111
Abstract
No abstract availableKeywords
Funding Information
- Doris Duke Charitable Foundation
This publication has 21 references indexed in Scilit:
- The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomyBJU International, 2007
- Phase I Trial of Intravesical Docetaxel in the Management of Superficial Bladder Cancer Refractory to Standard Intravesical TherapyJournal of Clinical Oncology, 2006
- Management of clinical T1 bladder transitional cell carcinoma by radical cystectomyUrologic Oncology: Seminars and Original Investigations, 2004
- Defining Bacillus Calmette-Guerin Refractory Superficial Bladder TumorsJournal of Urology, 2003
- New drugs and new approaches for the treatment of metastatic urothelial cancerWorld Journal of Urology, 2002
- Bladder tissue pharmacokinetics of intravesical taxolCancer Chemotherapy and Pharmacology, 1997
- A Randomized Multicenter Trial of Adjuvant Therapy in Superficial Bladder Cancer: Transurethral Resection Only Versus Transurethral Resection Plus Mitomycin C Versus Transurethral Resection Plus Bacillus Calmette-GuerinJournal of Urology, 1996
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987
- Long-Term Results and Complications of Intracavitary Bacillus Calmette-Guerin Therapy for Bladder CancerJournal of Urology, 1984
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976